GlaxoSmithKline PLC Director/PDMR Shareholding (8628K)
September 26 2016 - 12:02PM
UK Regulatory
TIDMGSK
RNS Number : 8628K
GlaxoSmithKline PLC
26 September 2016
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr R G Connor
=== ======================== ==============================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the Following the vesting on 23 September 2016
transaction of 50% of an award made on 12 June 2014
under the GlaxoSmithKline Deferred Investment
Award Plan, Mr R Connor will receive a
cash payment of GBP237,076.13 less applicable
tax withholding in respect of 14,376.963
notional Ordinary Shares.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------------------
GBP16.49 14,376.963 notional Ordinary
Shares.
--------- -----------------------------
=== ======================== ==============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2016-09-23
=== ======================== ==============================================
f) Place of the n/a
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr S A Hussain
=== ======================== ==============================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the Following the vesting on 23 September 2016
transaction of 50% of an award made on 12 June 2014
under the GlaxoSmithKline Deferred Investment
Award Plan, Mr Hussain will receive a cash
payment of GBP296,345.16 less applicable
tax withholding in respect of 17,971.204
notional Ordinary Shares.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------------------
GBP16.49 17,971.204 notional Ordinary
Shares
--------- -----------------------------
=== ======================== ==============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2016-09-23
=== ======================== ==============================================
f) Place of the n/a
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr D S Redfern
=== ======================== ==============================================
b) Position/status Chief Strategy Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the Following the vesting on 23 September 2016
transaction of 50% of an award made on 12 June 2014
under the GlaxoSmithKline Deferred Investment
Award Plan, Mr Redfern will receive a cash
payment of GBP237,076.13 less applicable
tax withholding in respect of 14,376.963
notional Ordinary Shares.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------------------
GBP16.49 14,376.963 notional Ordinary
Shares
--------- -----------------------------
=== ======================== ==============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2016-09-23
=== ======================== ==============================================
f) Place of the n/a
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Ms C Thomas
=== ======================== ==============================================
b) Position/status SVP, Human Resources
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the Following the vesting on 23 September 2016
transaction of 50% of an award made on 12 June 2014
under the GlaxoSmithKline Deferred Investment
Award Plan, Ms Thomas will receive a cash
payment of GBP237,076.13 less applicable
tax withholding in respect of 14,376.963
notional Ordinary Shares.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------------------
GBP16.49 14,376.963 notional Ordinary
Shares
--------- -----------------------------
=== ======================== ==============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2016-09-23
=== ======================== ==============================================
f) Place of the n/a
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===========================================================================
a) Name Dr P J T Vallance
=== ======================== =================================================
b) Position/status President, Pharmaceuticals Research & Development
=== ======================== =================================================
c) Initial notification/ Initial notification
amendment
=== ======================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===========================================================================
a) Name GlaxoSmithKline plc
=== ======================== =================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =================================================
b) Nature of the Following the vesting on 23 September 2016
transaction of 50% of an award made on 12 June 2014
under the GlaxoSmithKline Deferred Investment
Award Plan, Mr Vallance will receive a
cash payment of GBP296,345.16 less applicable
tax withholding in respect of 17,971.204
notional Ordinary Shares.
=== ======================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------------------
GBP16.49 17,971.204 notional Ordinary
Shares
--------- -----------------------------
=== ======================== =================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =================================================
e) Date of the transaction 2016-09-23
=== ======================== =================================================
f) Place of the n/a
transaction
=== ======================== =================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEQLFLQKFEBBK
(END) Dow Jones Newswires
September 26, 2016 12:02 ET (16:02 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
